|
1
|
Sun M, Jiang R, Li JD, et al: MED19
promotes proliferation and tumorigenesis of lung cancer. Mol Cell
Biochem. 355:27–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang CG, Wang RY, Sun M, Li JD, Gao N and
Zhang XY: In vivo antitumor effect of siRNA against STAT3 on
transplanted Lewis lung cancer in mice. Chem Res Chin Univ.
24:322–329. 2008.
|
|
3
|
Luo SL, Sun M, Jiamg R, Wang G and Zhang
XY: Establishment of primary mouse lung adenocarcinoma cell
culture. Oncol Lett. 2:629–632. 2011.PubMed/NCBI
|
|
4
|
Eymin B and Gazzeri S: Role of cell cycle
regulators in lung carcinogenesis. Cell Adh Migr. 4:114–123. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shintani S, Mihara M, Terakado N, et al:
Reduction of p12DOC-1 expression is a negative prognostic indicator
in patients with surgically resected oral squamous cell carcinoma.
Clin Cancer Res. 7:2776–2782. 2001.PubMed/NCBI
|
|
6
|
Shintani S, Ohyama H, Zhang X, et al:
p12(DOC-1) is a novel cyclin-dependent kinase 2-associated protein.
Mol Cell Biol. 20:6300–6307. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Todd R, McBride J, Tsuji T, et al: Deleted
in oral cancer-1 (doc-1), a novel oral tumor suppressor gene. FASEB
J. 9:1362–1370. 1995.PubMed/NCBI
|
|
8
|
Daigo Y, Suzuki K, Maruyama O, et al:
Isolation, mapping and mutation analysis of a human cDNA homologous
to the doc-1 gene of the Chinese hamster, a candidate tumor
suppressor for oral cancer. Genes Chromosomes Cancer. 20:204–207.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peng H, Shintani S, Kim Y and Wong DT:
Loss of p12CDK2-AP1 expression in human oral squamous cell
carcinoma with disrupted transforming growth factor-beta-Smad
signaling pathway. Neoplasia. 8:1028–1036. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hiyoshi Y, Watanabe M, Hirashima K, et al:
p12CDK2-AP1 is associated with tumor progression and a poor
prognosis in esophageal squamous cell carcinoma. Oncol Rep.
22:35–39. 2009.PubMed/NCBI
|
|
11
|
Zolochevska O and Figueiredo ML: Cell
cycle regulator cdk2ap1 inhibits prostate cancer cell growth and
modifies androgen-responsive pathway function. Prostate.
69:1586–1597. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zolochevska O and Figueiredo ML:
Expression of cell cycle regulator cdk2ap1 suppresses tumor cell
phenotype by non-cell-autonomous mechanisms. Oral Oncol.
45:e106–112. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zolochevska O and Figueiredo ML:
Cell-cycle regulators cdk2ap1 and bicalutamide suppress malignant
biological interactions between prostate cancer and bone cells.
Prostate. 71:353–367. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Choi MG, Sohn TS, Park SB, et al:
Decreased expression of p12 is associated with more advanced tumor
invasion in human gastric cancer tissues. Eur Surg Res. 42:223–229.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan Z, Gaba AG, Kent TS, Bennett A,
Miller A and Weber TK: Modulation of CDK2-AP1 [p12(DOC-1)]
expression in human colorectal cancer. Oncogene. 24:3657–3668.
2005.PubMed/NCBI
|
|
16
|
Figueiredo ML, Kim Y, St John MA and Wong
DT: p12CDK2-AP1 gene therapy strategy inhibits tumor growth in an
in vivo mouse model of head and neck cancer. Clin Cancer Res.
11:3939–3948. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cwikla SJ, Tsuji T, McBride J, Wong DT and
Todd R: doc-1-mediated apoptosis in malignant hamster oral
keratinocytes. J Oral Maxillofac Surg. 58:406–414. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Galetta D, Pisconti S, Cinieri S, et al:
Induction pemetrexed and cisplatin followed by maintenance
pemetrexed versus carboplatin plus paclitaxel plus bevacizumab
followed by maintenance bevacizumab: a quality of life-oriented
randomized phase III study in patients with advanced non-squamous
non-small-cell lung cancer (ERACLE). Clin Lung Cancer. 12:402–406.
2011.
|
|
19
|
Zolochevska O and Figueiredo ML: Novel
tumor growth inhibition mechanism by cell cycle regulator cdk2ap1
involves antiangiogenesis modulation. Microvasc Res. 80:324–331.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wong DT, Kim JJ, Khalid O, Sun HH and Kim
Y: Double edge: CDK2AP1 in cell-cycle regulation and epigenetic
regulation. J Dent Res. 91:235–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng J, Xue H, Wang T, et al: miR-21
downregulates the tumor suppressor P12 CDK2AP1 and stimulates cell
proliferation and invasion. J Cell Biochem. 112:872–880. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim Y, McBride J, Kimlin L, Pae EK,
Deshpande A and Wong DT: Targeted inactivation of p12, CDK2
associating protein 1, leads to early embryonic lethality. PLoS
One. 4:e45182009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wadler S: Perspectives for cancer
therapies with cdk2 inhibitors. Drug Resist Updat. 4:347–367. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang TY, Chang GC, Chen KC, et al:
Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by
pemetrexed leading to S-phase arrest and apoptosis in human
non-small cell lung cancer A549 cells. Eur J Pharmacol. 663:17–26.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim Y, McBride J, Zhang R, Zhou X and Wong
DT: p12(CDK2-AP1) mediates DNA damage responses induced by
cisplatin. Oncogene. 24:407–418. 2005. View Article : Google Scholar : PubMed/NCBI
|
